Campbell Capital Management Inc Bristol Myers Squibb CO Transaction History

Campbell Capital Management Inc

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 11, 2022	SELL	$61.48 - $73.72 $5.89 Million - $7.07 Million	-95,857 Closed	0 $0
Q4 2021 Jan 20, 2022	SELL	$53.63 - $62.52 $254,742 - $296,970	-4,750 Reduced 4.72%	95,857 $5.98 Million
Q3 2021 Oct 14, 2021	SELL	$59.17 - $69.31 $240,230 - $281,398	-4,060 Reduced 3.88%	100,607 $5.95 Million
Q2 2021 Jul 09, 2021	SELL	$61.91 - $67.42 $105,247 - $114,614	-1,700 Reduced 1.6%	104,667 $6.99 Million
Q1 2021 Apr 06, 2021	SELL	$59.34 - $66.74 $54,236 - $61,000	-914 Reduced 0.85%	106,367 $6.72 Million

Q4 2020 Jan 13, 2021	BUY	$57.74 - $65.43 $7,044 - $7,982	122 Added 0.11%	107,281 $7.02 Million
Q3 2020 Oct 01, 2020	BUY	$57.43 - $63.64 $3.48 Million - $3.85 Million	60,550 Added 129.91%	107,159 $6.46 Million
Q2 2020 Jul 08, 2020	BUY	$54.82 - $64.09 $210,508 - $246,105	3,840 Added 8.98%	46,609 $2.74 Million
Q1 2020 Apr 10, 2020	SELL	$46.4 - $67.43 $99,296 - $144,300	-2,140 Reduced 4.77%	42,769 $2.38 Million
Q4 2019 Jan 09, 2020	SELL	$49.21 - $64.19 $31,986 - $41,723	-650 Reduced 1.43%	44,909 $2.88 Million
Q3 2019 Oct 01, 2019	BUY	$42.77 - $50.71 $607,334 - $720,082	14,200 Added 45.28%	45,559 $2.31 Million
Q2 2019 Jul 18, 2019	SELL	$44.62 - $49.34 $53,544 - $59,208	-1,200 Reduced 3.69%	31,359 $1.42 Million
Q1 2019 Apr 09, 2019	SELL	$45.12 - $53.8 $9,024 - $10,760	-200 Reduced 0.61%	32,559 $1.55 Million
Q4 2018 Feb 15, 2019	BUY	$48.76 - $63.23 $1.6 Million - $2.07 Million	32,759 New	32,759 $1.7 Million

2,553

1.49B

25.9M

20M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $84.3B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Campbell Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Campbell Capital Management Inc with notifications on news.